Maintenance of clinical remission · Participants with Crohn's disease in remission
Methotrexate probably leads to higher proportion of patients maintaining clinical remission compared with placebo (moderate certainty).
3 findings from 1 review
RR 1.57 [1.1, 2.23]
2 studies · 98 participants
Moderate
RR 1.67 [1.05, 2.67]
1 study · 76 participants
Moderate
RR 1.35 [0.86, 2.12]
1 study · 22 participants
Low
OutcomesTime frame of absolute effects · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
OutcomesTime frame of absolute effects · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment responsea · children and young people with JIA
Methotrexate showed no clear difference in treatment responsea(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
1 finding from 1 review
Sustained clinically inactive diseasec · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment responsea · children and young people with JIA
Methotrexate may leads to higher treatment responsea(up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
Function · children and young people with JIA
1 finding from 1 review
Pain · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global well‐being: rated by participants · children and young people with JIA
1 finding from 1 review
Serious adverse events(4 months) · children and young people with JIA
Methotrexate showed no clear difference in serious adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · children and young people with JIA
Methotrexate showed no clear difference in withdrawals due to adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
1 finding from 1 review
Sustained clinically inactive diseasec · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Function · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain on motion · children and young people with JIA
1 finding from 1 review
Global well‐being: rated by participants · children and young people with JIA
Methotrexate showed no clear difference in participant global assessment of well‐being(up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events(up to 6 months) · children and young people with JIA
Methotrexate showed no clear difference in serious adverse events(up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · children and young people with JIA
Methotrexate showed no clear difference in withdrawals due to adverse events (up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
Disease response · psoriatic arthritis
Methotrexate may leads to higher disease response compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life ‐ not measured · psoriatic arthritis
The review found no eligible studies for this question.
1 finding from 1 review
Disease activity ‐ not measured · psoriatic arthritis
The review found no eligible studies for this question.
1 finding from 1 review